Dr. Parveen Jain
Senior Consultant & HOD
Oncology
20+ years of experience
Aakash Healthcare Super Speciality Hospital, Dwarka New Delhi
Opening Hours
Monday – Friday 8.00 – 7:00 pm
Saturday 9.00 – 8.00 pm
Sunday 10.00 – 9.00 pm
About Doctor
- Dr. Parveen Jain has been working in the field of Medical Oncology for 20 years.
- He has a vast experience in the management of both hematological & non hematological malignancies (breast, lung, GI malignancies, and other solid tumors).
- He cleared the “European Certified Medical Oncologist” exam conducted by ESMO Medical Oncology.
- He has also done preceptorship in Prostate cancer and Lung cancer conducted by the European Society of Medical Oncology in Singapore.
- Dr. Parveen Jain has a keen interest in conducting clinical research. He has participated as a Co-investigator in various phase II, III & IV clinical trials.
- He also has numerous publications in his credit in various national and international journals.
Qualification & Training
- MBBS – Manipal Academy Of Higher Education, Manipal, India
- DNB (General Medicine) – National Board Of Examination
- DNB (Medical Oncology) – National Board Of Examination
- ECMO (Medical Oncology)
Areas of Clinical interests
- Chronic Leukemias
- Lymphomas
- Plasma cell disorders.
- Targeted therapies
- Immunotherapies
- Oncologic emergencies
- Palliative care and Metronomic therapy
- Breast Cancer
- Lung Cancer
- Gastrointestinal Cancer
- Gynecological Cancers
- Sarcomas
Awards:
- Awarded Prize for Oral paper presentation at RGCON 2017 titled “To evaluate the role of Ki-67 index as a predictor of response to neoadjuvant chemotherapy in breast cancer”.
- Award Poster Presentation at ISMPO ISOCON 2015 titled “To analyze the Epidemiological & Molecular profile of patients with metastatic adenocarcinoma lung presenting to a single unit of a tertiary cancer center (RGCI & RC) in North India”.
Memberships:
- European Society for Medical Oncology
- Indian Society of Oncology
List of Treatments
- Targeted therapies
- Immunotherapies
- Oncologic emergencies
- Palliative care and Metronomic therapy
- Plasma cell neoplasms
- Sarcomas
- Gastrointestinal Cancer
- Gynecological Cancers
- Metastatic Tumors Treatment
- Adrenal Cancer Treatment
- Anal Cancer Treatment
- Bile Duct Cancer Treatment
- Bladder Cancer Treatment
- Breast Cancer-Surgical
- Cancer in Children
- Carcinoma of Unknown Primary (CUP) Treatment
- Castleman Disease Treatment
- Cervical Cancer Treatment
- Endometrial Cancer Treatment
- Esophagus Cancer Treatment
- Ewing Family of Tumors Treatment
- Eye Cancer Treatment
- Gallbladder Cancer Treatment
- Laryngeal and Hypopharyngeal Cancer Treatment
- Leukemia in Children
- Liver Cancer
- Lung Cancer Treatment
- Non-Small Cell Lung Cancer (NSCLC) Treatment
- Small-cell Carcinoma Treatment
- Lung Carcinoid Tumor Treatment
- Skin Lymphoma Treatment
- Malignant Mesothelioma Treatment
- Nasopharyngeal Cancer Treatment
- Neuroblastoma
- Non-Hodgkin Lymphoma (NHL) Treatment
- Non-Hodgkin Lymphoma In Children
- Oral Cavity and Oropharyngeal Cancer
- Ovarian Cancer Surgery
- Pancreatic Cancer
- Penile Cancer Treatment
- Prostate Cancer-Surgical
- Retinoblastoma (RB) Treatment
- Gestational Trophoblastic Disease (GTD) Treatment
- Hodgkin Disease Treatment